Scopus BioPharma

About

Headcount over time

Offices

Q&A

What is Scopus BioPharma's primary focus?

Scopus BioPharma is a clinical-stage biopharmaceutical company focused on developing transformational therapeutics for serious diseases with unmet medical needs, particularly in immuno-oncology and other serious diseases like systemic sclerosis.

When was Scopus BioPharma founded?

Scopus BioPharma was founded in 2018.

How many employees does Scopus BioPharma currently have?

As of August 2026, Scopus BioPharma has 13 employees.

What was Scopus BioPharma's initial funding round?

In June 2019, Scopus BioPharma raised a Seed round of $2,000,000, with HCFP participating.

When did Scopus BioPharma conduct a public offering?

In December 2020, Scopus BioPharma completed a Public Offering, raising $10,350,000. Benchmark and The Benchmark Company, LLC were involved.

Who is the Chairman of the Board and Principal Executive Officer of Scopus BioPharma?

Joshua R. Lamstein has served as the Chairman of the Board and Principal Executive Officer since 2017.

Does Scopus BioPharma have any subsidiaries?

Yes, Scopus BioPharma has a wholly-owned Israel-based subsidiary, Scopus BioPharma Israel Ltd., and a majority-owned subsidiary for immuno-oncology programs, Duet BioTherapeutics Inc.

Who is the President of Immuno-Oncology at Scopus BioPharma and CEO of Duet BioTherapeutics?

Alan M. Horsager has held the position of President - Immuno-Oncology and President and Chief Executive Officer of Duet BioTherapeutics since July 2021.

Team · 8

Joshua R. Lamstein

Founder · Chairman of the Board, Principal Executive Officer

Robert J. Gibson

Vice Chairman of the Board, Treasurer, Secretary

Alan M. Horsager

President - Immuno-Oncology and President and Chief Executive Officer of Duet BioTherapeutics

Aharon Schwartz

Executive Chairman of Scopus BioPharma Israel Ltd.

Ira Scott Greenspan

Director

David A. Buckel

Independent Director

Raphael Hofstein

Independent Director

David Weild

Independent Director